Home/Research library/Gobburu et al. (1999)
Study in humans · 1999 · cited for Ipamorelin

Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers

Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmaceutical research 1999;16(9):1412-6. doi:10.1023/a:1018955126402 · PubMed 10496658

In brief

The only human study of ipamorelin cited on this site, and it is a pharmacokinetic one. Healthy male volunteers received one of five 15-minute intravenous infusions, and ipamorelin and growth hormone were measured in blood. Ipamorelin exposure rose in proportion to dose; the terminal half-life was about two hours, clearance 0.078 litres per hour per kilogram, and steady-state volume of distribution 0.22 litres per kilogram. Growth hormone rose in a single episode that peaked at about 40 minutes and then fell exponentially to negligible levels at every dose. The authors fitted an indirect-response model in which ipamorelin drives a finite burst of growth-hormone release; half-maximal stimulation occurred at 214 nanomoles per litre. Between-subject variability was larger for the hormone response than for the drug levels.

Study design

Dose-escalation pharmacokinetic and pharmacodynamic study: five intravenous infusion rates over 15 minutes, eight healthy men per level.

What it does not show

Intravenous infusion in healthy men, single administrations, hormone levels as the only outcome. It characterises disposition and the shape of the growth-hormone pulse; it is not an efficacy or safety study and says nothing about subcutaneous use.

A clinical trial tests a pharmaceutical form of a compound, in a defined patient group, under medical supervision, with a defined endpoint. None of that transfers to a research-grade vial, and this page does not suggest it does.

Where this paper is cited

  • Ipamorelin — Pharmacokinetic–pharmacodynamic model in human volunteers: dose-dependent growth hormone release with a short plasma half-life.

Other papers cited for Ipamorelin

Further reading

How this page was made: the citation was retrieved from PubMed by PMID and checked against the title on the product page; the summary was written from the paper's abstract and reports only what the abstract reports. Read the paper itself before relying on any figure here.

Research use only This page summarises a published paper. It is not a claim that any product sold by Zyrna Research does what the paper describes, the trial used a pharmaceutical product under medical supervision, and nothing here is dosing guidance. Nothing sold by Zyrna Research is for human or veterinary use.